Cameron Turtle
Chief Executive Officer chez SPYRE THERAPEUTICS, INC.
Fortune : 28 M $ au 31/03/2024
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Russell Cox | M | 60 | 9 ans | |
Tomas Kiselak | M | 38 | 1 ans | |
Peter Harwin | M | 38 | 1 ans | |
Michael Henderson | M | 34 | 1 ans | |
Heidy Abreu King-Jones | F | 41 | 1 ans | |
Scott Burrows | M | 47 | 1 ans | |
Jeffrey Albers | M | 52 | 1 ans | |
Scott W. Rowlinson | M | 56 | 10 ans | |
Laurie Stelzer | F | 56 | 1 ans | |
Mark Mckenna | M | 48 | - | |
Paul Fehlner | M | 61 | 1 ans | |
Joshua Friedman | M | - | 1 ans | |
Deanna Nguyen | M | - | 1 ans | |
Mira Huyghe | F | - | 1 ans | |
Brian Connolly | M | - | 1 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Armen Shanafelt | M | 64 | 10 ans | |
Ivana Magovcevic-Liebisch | M | 55 | 5 ans | |
V. Lawlis | M | 72 | 5 ans | |
Hunter Smith | M | 56 | 2 ans | |
Alison Lawton | F | 62 | 4 ans | |
Cortney Caudill | F | - | 4 ans | |
Marcio Souza | M | 45 | 2 ans | |
Shafique Virani | M | 53 |
CoA Therapeutics, Inc.
CoA Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., CoA Therapeutics, Inc. is a biotechnology company based in San Francisco, CA. The private company is targeting coenzyme-A (CoA) for patients with PKAN, organic acidurias, and other diseases of CoA sequestration. CoA plays a crucial role in energy metabolism and is implicated in a large number of disorders, from ultra-rare diseases like pantothenate kinase-associated neurodegeneration (PKAN) and organic acidurias (OAs), to common diseases such as type 2 diabetes. CoA Therapeutics is developing a novel small-molecule approach to modulate CoA levels by leveraging recent research about the CoA synthetic pathway. The company's approach and lead compounds are based on breakthrough scientific developments led by Suzanne Jackowski, Charles Rock, Richard Lee, and Stephen White at St. Jude Children's Research Hospital.
Navire Pharma, Inc.
Navire Pharma, Inc. Pharmaceuticals: MajorHealth Technology Navire Pharma, Inc. engages in the development of therapeutics to treat multiple cancers. It focuses on SHP2, a protein-tyrosine phosphatase that links growth factor, cytokine and integrin signalling with the downstream RAS/ERK MAPK pathway to regulate cellular proliferation and survival. The company was founded by Phil Jones and Benjamin Neel in 2017 and is headquartered in San Francisco, CA. | 2 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 23 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Cameron Turtle
- Réseau Personnel